{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:10:12Z","timestamp":1762542612795},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.semnephrol.2016.08.009","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T17:05:03Z","timestamp":1481735103000},"page":"481-488","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Back to the Future: Paving the Way for the Next Generation of Renal Therapeutics"],"prefix":"10.1016","volume":"36","author":[{"given":"Louis","family":"Brenner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2016.08.009_bib1","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease website. http:\/\/www.cdc.gov\/ckd. Accessed March 5, 2015"},{"issue":"Suppl 1","key":"10.1016\/j.semnephrol.2016.08.009_bib2","first-page":"S1","article-title":"US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib3","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.ASN.0000014251.87778.01","article-title":"Cumulative risk for developing end-stage renal disease in the US population","volume":"13","author":"Kiberd","year":"2002","journal-title":"JASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib4","unstructured":"http:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/Pages\/kidney-disease-statistics-united-states.aspx#7"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib5","unstructured":"http:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/Pages\/kidney-disease-statistics-united-states.aspx#17"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1500848","article-title":"The $2.6 billion pill\u2014methodological and policy considerations","volume":"372","author":"Avorn","year":"2015","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.ajkd.2011.06.006","article-title":"Trial quality in nephrology; How are we measuring up?","volume":"58","author":"Palmer","year":"2011","journal-title":"AJKD"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2215\/CJN.00500115","article-title":"Optimizing enrollment of patients into nephrology research studies","volume":"11","author":"Selewski","year":"2015","journal-title":"CJASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as a target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib12","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI46263","article-title":"Genetics of kidney failure and the evolving story of APOL1","volume":"121","author":"Friedman","year":"2011","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12882-015-0090-9","article-title":"Focal segmental glomerulosclerosis: molecular genetics and targeted therapies","volume":"16","author":"Chen","year":"2015","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2215\/CJN.06380613","article-title":"Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1","volume":"9","author":"Bleyer","year":"2014","journal-title":"CJASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5527\/wjn.v4.i2.235","article-title":"Primary and secondary hyperoxaluria: Understanding the enigma","volume":"4","author":"Bhasin","year":"2015","journal-title":"World Journal of Nephrology"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"AJKD"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR Decline as an End Point in Trials of CKD: A Viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"AJKD"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib19","unstructured":"European Medicines Agency. Draft guideline on the clinical investigation of medicinal products to prevent development\/slow progression of chronic renal insufficiency (EMA\/CHMP\/355988\/2014). 2014. http:\/\/www.ema.europa.eu\/ema\/doc_index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500169469&murl=menus\/document_library\/document_library.jsp&mid=0b01ac058009a3dc. Accessed 17.01.25"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate endpoints for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"CJASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2014.02.020","article-title":"Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis","volume":"61","author":"Inker","year":"2014","journal-title":"AJKD"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib22","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"JASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"AJKD"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib25","unstructured":"MD Anderson Cancer Center. Cancer Moonshots Program. https:\/\/www.mdanderson.org\/education-and-research\/research-at-md-anderson\/basic-science\/research-programs\/lung-cancer-research-program\/battle-grant\/index.html; Accessed 17.01.25"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib28","unstructured":"http:\/\/www.cancermoonshots.org\/"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/01.ASN.0000112129.20838.3F","article-title":"The Chronic Kidney Disease Initiative","volume":"15","author":"Parker","year":"2004","journal-title":"JASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib30","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1681\/ASN.2015090976","article-title":"Overcoming barriers in kidney health\u2014forging a platform for innovation","volume":"27","author":"Linde","year":"2016","journal-title":"JASN"},{"key":"10.1016\/j.semnephrol.2016.08.009_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"NEJM"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T01:24:14Z","timestamp":1536197054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929516300821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0270929516300821"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.08.009","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Back to the Future: Paving the Way for the Next Generation of Renal Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}